Apixaban Chemical Structure (Apixaban Struct)
Chemical structure of apixaban, the active ingredient in ELIQUIS 5 mg film-coated tablets.*
Eliquis Tablet, Film Coated
Product Images NDC 50090-6454
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 50090-6454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aristotle Forest Plot (Eliquis Clin Forest Fig5)
A forest plot comparing the hazard ratio of apixaban versus warfarin across multiple patient subgroups, including age, sex, weight, prior stroke, diabetes, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. The plot shows event counts, patients, and hazard ratios with 95% confidence intervals for each subgroup.*
Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)
A forest plot comparing the hazard ratios of apixaban versus warfarin across various patient subgroups based on factors such as prior warfarin status, age, sex, weight, prior stroke/TIA, diabetes mellitus, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. The chart visually indicates whether apixaban or warfarin is favored for each subgroup with markers and confidence intervals.*
Aristotle Kaplan-meier Curve (Eliquis Km Fig4)
A Kaplan-Meier curve comparing the proportion of subjects with stroke or systemic embolism over 36 months for ELIQUIS (apixaban) and Warfarin. The chart includes hazard ratio, p-value, and the number of subjects at risk over time for each treatment group.*
Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)
A forest plot chart shows the fold change and 90% confidence intervals in pharmacokinetics (Cmax and AUC) of Eliquis (apixaban) when co-administered with various interacting drugs. The chart groups drugs into combined P-gp and strong CYP3A4 inhibitors, other inhibitors, and combined P-gp and strong CYP3A4 inducers, depicting changes relative to reference values for each drug interaction.*
O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)
A pharmacokinetic chart showing fold changes and 90% confidence intervals for apixaban (ELIQUIS) in various populations, including renal impairment stages, age groups, body weight categories, and hepatic impairment. The chart compares Cmax and AUC values relative to reference, with dosage recommendations noted, mostly indicating no dose adjustment needed.*
Label Image (Lbl500906454)
Label for ELIQUIS 5 mg film-coated tablets by A-S Medication Solutions. It lists the active ingredient apixaban, dosage strength 5 mg, quantity of 60 tablets, and storage instructions to keep at 68 to 77 degrees Fahrenheit. The label includes product and lot numbers, and a QR code linking to dosage information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
